Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder

NCT05266716 is registered in ClinicalTrials.gov with Affect Therapeutics, Inc. as lead sponsor.

NCT NCT05266716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05266716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Field Study of a Digital Therapeutic Platform to Facilitate Treatment for Methamphetamine-Primary Stimulant Use Disorder
Lead sponsor
Affect Therapeutics, Inc.
Phase
Not applicable
Overall status
Completed
Start date
February 18, 2021
Completion date
January 7, 2022
Enrollment
79 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

methamphetamine abuse